Team
Team
A team of experts building global biotech partnerships.
A team of experts building global biotech partnerships.
A team of experts building global biotech partnerships.
Leadership
Leadership
Leadership
The team at Liberi C Cube Lab goes beyond advisory roles, acting as execution-driven professionals who deliver partnerships for results.
The team at Liberi C Cube Lab goes beyond advisory roles, acting as execution-driven professionals who deliver partnerships for results.
The team at Liberi C Cube Lab goes beyond advisory roles, acting as execution-driven professionals who deliver partnerships for results.
Tae Joon Chin
Tae Joon Chin
Tae Joon Chin
Tae Joon Chin is a hybrid management and business development expert with a background as a New York–licensed attorney, combining venture investment, management consulting, corporate strategy, and cross-border legal experience. He has led over 400 venture acceleration and advisory engagements—from early-stage startups to mid-sized companies—shaping growth strategies across biotech, pharma, ICT, and convergent technologies in Korea.
진태준 대표는 뉴욕주 변호사 출신으로, 벤처 투자·경영 컨설팅·대기업 전략·해외 법무 경험을 모두 갖춘 하이브리드형
경영·BD 전문가입니다. 유망 스타트업부터 중견기업까지 400건 이상의 벤처 액셀러레이션과 자문을 수행하며
국내 바이오·제약·ICT·융합기술 분야의 성장 전략을 구축해왔습니다.
진태준 대표는 뉴욕주 변호사 출신으로, 벤처 투자·경영 컨설팅·대기업 전략·해외 법무 경험을 모두 갖춘 하이브리드형 경영·BD 전문가입니다.
유망 스타트업부터 중견기업까지 400건 이상의 벤처 액셀러레이션과 자문을 수행하며 국내 바이오·제약·ICT·융합기술 분야의 성장 전략을 구축해왔습니다.
Key Experience
U.S. Lawyer (New York)
Executive Vice President, Neoplux
(now Shinhan Venture Investment)Executive Vice President, Doosan Group Holding Company
Partner, Deloitte Consulting
CEO, Nemo Partners
Manager, McKinsey & Company
Areas of Expertise
Venture acceleration & investment: advisory for 400+ startups and scale-ups (biotech, pharma, ICT, convergence technologies)
Restructuring and M&A advisory: execution of deals for 25 companies
Education
University of Washington Law School (J.D.)
Seoul National University, College of Law (B.A.)
Key Experience
U.S. Lawyer (New York)
Executive Vice President, Neoplux
(now Shinhan Venture Investment)Executive Vice President, Doosan Group Holding Company
Partner, Deloitte Consulting
CEO, Nemo Partners
Manager, McKinsey & Company
Areas of Expertise
Venture acceleration & investment: advisory for 400+ startups and scale-ups (biotech, pharma, ICT, convergence technologies)
Restructuring and M&A advisory: execution of deals for 25 companies
Education
University of Washington Law School (J.D.)
Seoul National University, College of Law (B.A.)
Frans W.G. Trouwen
Frans W.G. Trouwen
Frans W.G. Trouwen
Frans W.G. Trouwen is a global life science business leader who has founded and led multiple organizations across life sciences, biotech, and data sectors in Europe and the United States. He has served as CEO, chairman, and board member in multiple countries, bringing extensive experience in global partnerships, investment, and business development strategy.
프란스 트라웬 회장은 유럽·미국을 중심으로 라이프사이언스·바이오텍·데이터 분야에서
다수의 조직을 설립·리드해온 글로벌 바이오 비즈니스 리더입니다.
다양한 국가에서 CEO, 회장, 이사회 멤버 역할을 수행하며 글로벌 파트너십, 투자, BD 전략에서 폭넓은 경험을 갖고 있습니다.
프란스 트라웬 회장은 유럽·미국을 중심으로 라이프사이언스·
바이오텍·데이터 분야에서 다수의 조직을 설립·리드해온 글로벌
바이오 비즈니스 리더입니다.
다양한 국가에서 CEO, 회장, 이사회 멤버 역할을 수행하며
글로벌 파트너십, 투자, BD 전략에서 폭넓은 경험을 갖고 있습니다.
Key Experience
Founder & Former CEO, Valletta Health Biotech (Amsterdam)
Founder & CEO, Liberi Group (Amsterdam)
Chairman of the Board, Rodina Technologies Holding (Data, Amsterdam)
Chairman of the Board, Liberi Group
Chairman of the Board, Modulation Therapeutics (Morgantown, USA, 2024–)
Board Member, Tradewind Bioscience (California, USA, 2024–)
Chairman of the Board, Liberi–C Cube Lab Joint Venture (Seoul, 2025–)
Managing Director, Innocom BioEquities (VC, California, 2025–)
Areas of Expertise
Global business development and partnership leadership
Formation and expansion of biotech and data companies in Europe and the United States
Strategic advisory and connectivity across global VC and biotech investment ecosystems
Key Experience
Founder & Former CEO, Valletta Health Biotech (Amsterdam)
Founder & CEO, Liberi Group (Amsterdam)
Chairman of the Board, Rodina Technologies Holding (Data, Amsterdam)
Chairman of the Board, Liberi Group
Chairman of the Board, Modulation Therapeutics (Morgantown, USA, 2024–)
Board Member, Tradewind Bioscience (California, USA, 2024–)
Chairman of the Board, Liberi–C Cube Lab Joint Venture (Seoul, 2025–)
Managing Director, Innocom BioEquities (VC, California, 2025–)
Areas of Expertise
Global business development and partnership leadership
Formation and expansion of biotech and data companies in Europe and the United States
Strategic advisory and connectivity across global VC and biotech investment ecosystems
Team Members
Team Members
Saeyeon Ann
Team Lead
Chaerin Jeong
Senior Consultant
Jimin Lee
Senior Consultant
Soye Pi
Junior Consultant
Thomas Trouwen
CFO(Chief Financial Offier)
Bram de Jong
Senior Manager
Hector de la Puebla Benito
Manager
Kim Dehaen
Consultant
Team Members
안세연(Saeyeon Ann)
팀장(Team Lead)
정채린(Chaerin Jeong)
수석(Senior Consultant)
이지민(Jimin Lee)
수석(Senior Consultant)
피소예(Soye Pi)
책임(Junior Consultant)
핌 체루티(Pim Cerutti)
COO
브람 더 용(Bram de Jong)
시니어 매니저
(Senior Corporate Development Manager)
엑토르 데 라 푸에블라 베니토
(Hector de la Puebla Benito)
매니저(Manager)
킴 데하엔(Kim Dehaen)
컨설턴트(Consultant)
Network
Network
Network
Despite world-class technologies, Korean biotech companies
still face significant barriers to global market entry.
Despite world-class technologies, Korean biotech companies
still face significant barriers to global market entry.
Despite world-class technologies, Korean biotech companies
still face significant barriers to global market entry.
The network of Liberi C Cube Lab is not a list of numbers, but a trust-based relationship
network validated through numerous projects and real collaborations.
The network of Liberi C Cube Lab is not a list of numbers, but a trust-based relationship
network validated through numerous projects and real collaborations.
리베리씨큐브랩이 가진 네트워크는 단순한 숫자의 나열이 아닌,
수많은 프로젝트와 실질적 협력을 통해 검증된, 신뢰할 수 있는 관계망입니다.
Domestic Network
Liberi C Cube Lab is built upon a nationwide network of pharmaceutical companies, biotech firms, and investors across Korea. This network is not static data, but a collection of trusted partnerships proven through
real-world collaboration. Through this foundation,
clients build stability at home and prepare confidently
for global expansion.
Global Network
We are connected to more than 9,000 global partners across Asia, Europe, and North America. Leveraging extensive collaboration experience with large, mid-sized, and emerging global pharma and biotech companies, we help Korean biotech and pharma companies secure the most realistic and compelling pathways to international markets. This network represents not just access, but a proven route to real outcomes.
Domestic Network
Liberi C Cube Lab is built upon a nationwide network of pharmaceutical companies, biotech firms, and investors across Korea. This network is not static data, but a collection of trusted partnerships proven through
real-world collaboration. Through this foundation,
clients build stability at home and prepare confidently
for global expansion.
Global Network
We are connected to more than 9,000 global partners across Asia, Europe, and North America. Leveraging extensive collaboration experience with large, mid-sized, and emerging global pharma and biotech companies, we help Korean biotech and pharma companies secure the most realistic and compelling pathways to international markets. This network represents not just access, but a proven route to real outcomes.
Domestic Network
Liberi C Cube Lab is built upon a nationwide network of pharmaceutical companies, biotech firms, and investors across Korea. This network is not static data, but a collection of trusted partnerships proven through
real-world collaboration. Through this foundation,
clients build stability at home and prepare confidently
for global expansion.
Global Network
We are connected to more than 9,000 global partners across Asia, Europe, and North America. Leveraging extensive collaboration experience with large, mid-sized, and emerging global pharma and biotech companies, we help Korean biotech and pharma companies secure the most realistic and compelling pathways to international markets. This network represents not just access, but a proven route to real outcomes.